News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Obecure Achieves Successful Results in Its Proof of Concept Clinical Study Evaluating the Ability of Histalean(TM) to Mitigate Weight Gain Associated With Olanzapine


6/15/2009 9:47:44 AM

RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd. (TASE:BOLT), announces a positive outcome of its BET-209 clinical study, a randomized, double-blinded, placebo-controlled, four week Phase Ib, Proof-of-Concept (POC) study evaluating both the safety and the ability of HistaleanTM to mitigate the weight gain side effect associated with the anti psychotic drug, Olanzapine.

Read at BioSpace.com


comments powered by Disqus
Obecure
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES